Xist RNA in action: Past, present, and future

PLoS Genet. 2019 Sep 19;15(9):e1008333. doi: 10.1371/journal.pgen.1008333. eCollection 2019 Sep.

Abstract

In mammals, dosage compensation of sex chromosomal genes between females (XX) and males (XY) is achieved through X-chromosome inactivation (XCI). The X-linked X-inactive-specific transcript (Xist) long noncoding RNA is indispensable for XCI and initiates the process early during development by spreading in cis across the X chromosome from which it is transcribed. During XCI, Xist RNA triggers gene silencing, recruits a plethora of chromatin modifying factors, and drives a major structural reorganization of the X chromosome. Here, we review our knowledge of the multitude of epigenetic events orchestrated by Xist RNA to allow female mammals to survive through embryonic development by establishing and maintaining proper dosage compensation. In particular, we focus on recent studies characterizing the interaction partners of Xist RNA, and we discuss how they have affected the field by addressing long-standing controversies or by giving rise to new research perspectives that are currently being explored. This review is dedicated to the memory of Denise Barlow, pioneer of genomic imprinting and functional long noncoding RNAs (lncRNAs), whose work has revolutionized the epigenetics field and continues to inspire generations of scientists.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dosage Compensation, Genetic / genetics*
  • Dosage Compensation, Genetic / physiology
  • Epigenesis, Genetic / genetics
  • Female
  • Gene Silencing / physiology
  • Humans
  • Male
  • Mammals / genetics
  • RNA, Long Noncoding / genetics*
  • RNA, Long Noncoding / metabolism*
  • RNA, Long Noncoding / physiology
  • X Chromosome / genetics
  • X Chromosome Inactivation / genetics

Substances

  • RNA, Long Noncoding
  • XIST non-coding RNA

Grants and funding

E.H. is supported by a European Research Council Advanced Investigator award (AdG250367); European Union Seventh Framework Programme grants SYBOSS (GA242129) and MODHEP (GA259743). A.L. is supported by a European Marie Skłodowska-Curie Actions (MSCA) Individual fellowship (IF-838408). The funders had no role in the preparation of the article.